Radio-protective effect of sodium meclofenamate. A prospective clinical trial
- Sisters of Charity Hospital, Buffalo, NY (USA)
Twentyfour patients treated with irradiation to either their pelvis or their chest for neoplastic disease were included in a randomized study of radioprotection with sodium meclofenamate (Meclomen) (SM). Seventeen patients received SM 100 mg, p.os, t.i.d., and seven received placebo. The long-range radiation related chronic gastrointestinal and urinary tract toxicity was diminished by SM. At 12 months post irradiation, SM treated patients experienced less gastrointestinal and urinary symptoms, as well as less measured bladder contraction, than the controls. Acute gastrointestinal signs of radiotoxicity, however, seemed to have been enhanced by SM. The treated patients suffered from nausea, vomiting, and diarrhea. These acute toxic effects were temporary and reversible.
- OSTI ID:
- 5024909
- Journal Information:
- Journal of Medicine (Westbury, New York); (USA), Vol. 20:3-4; ISSN 0025-7850
- Country of Publication:
- United States
- Language:
- English
Similar Records
Prophylactic ibuprofed administration during pelvic irradiation
Prevention of acute radiation-induced proctosigmoiditis by balsalazide: A randomized, double-blind, placebo controlled trial in prostate cancer patients
Related Subjects
GASTROINTESTINAL TRACT
RADIATION PROTECTION
RADIOPROTECTIVE SUBSTANCES
RADIOSENSITIVITY EFFECTS
BLADDER
CHEST
NEOPLASMS
PATIENTS
RADIATION INJURIES
BIOLOGICAL EFFECTS
BIOLOGICAL RADIATION EFFECTS
BODY
BODY AREAS
DIGESTIVE SYSTEM
DISEASES
DRUGS
INJURIES
ORGANS
RADIATION EFFECTS
URINARY TRACT
560151* - Radiation Effects on Animals- Man